Cowen Downgrades Complete Genomic (GNOM) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall Street set for weekly gains with earnings, inflation data on tap
- Oil falls as Trump comments on Iran talks ease supply fears
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts GNOM Hot Sheet
Price: $68.60 +4.21%
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
Cowen downgraded Complete Genomic (NASDAQ: GNOM) from Outperform to Neutral.
For more ratings news on Complete Genomic click here and for the rating history of Complete Genomic click here.
Shares of Complete Genomic closed at $17.11 yesterday.
For more ratings news on Complete Genomic click here and for the rating history of Complete Genomic click here.
Shares of Complete Genomic closed at $17.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northland Downgrades Astera Labs (ALAB) to Market Perform
- BofA Securities Downgrades Smithfield Foods (SFD) to Neutral
- Northland sees AI bubble parallels with dotcom era, cuts two stocks
Create E-mail Alert Related Categories
DowngradesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
